Panama vs Zambia: Average cost of multi drug-resistant tuberculosis treatment
Panama
572 constant 2022 US$
in 2024
Zambia
600 constant 2022 US$
in 2024
Panama rank
74th
Zambia rank
72nd
Average cost of multi drug-resistant tuberculosis treatment over time
- Panama
- Zambia
How they compare
Zambia currently reports 600 constant 2022 US$ against 572 constant 2022 US$ in Panama, a difference of 28 constant 2022 US$.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Panama ahead.
Panama ranks 74th and Zambia ranks 72nd of 92 countries.
Zambia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Panama | Zambia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 5,436 constant 2022 US$ | 5,822 constant 2022 US$ | 385.5 constant 2022 US$ | Zambia |
| 2020s | 1,288 constant 2022 US$ | 2,897 constant 2022 US$ | 1,609 constant 2022 US$ | Zambia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Panama or Zambia?
- Zambia, at 600 constant 2022 US$ against 572 constant 2022 US$ in Panama as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Panama and Zambia?
- 28 constant 2022 US$, with Zambia ahead.
- How many years of comparable data are there for Panama and Zambia?
- 5 years are reported by both, from 2017 to 2024.
- How do Panama and Zambia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Panama ranks 74th and Zambia ranks 72nd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.